facebook button D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer

Sponsor: AstraZeneca

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.